GALAD_Model_for_Hepatocellular_Carcinoma_HCC_guideline v.1
GALAD Model for Hepatocellular Carcinoma (HCC) diagnoses HCC based on serum biomarkers in patients with chronic liver disease (CLD).
To estimate the risk that a CLD patient has HCC using only tumor markers and demographics (i.e., no imaging).
Use in patients with chronic liver disease (CLD). Formula GALAD Score = -10.08 + 0.09 x A + 1.67 x G + 2.34 log10(AF) + 0.04 x L + 1.33 x log10(D) Where variables are as follows: Gender: 0 if female, 1 if male Age: Age, years AFP-L3: Alpha fetoprotein L3, % AFP: Alpha fetoprotein, ng/mL DCP: Des-carboxy-prothrombin, ng/mL
1. Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014;23(1):144-53. 2. Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol. 2016;54(12):1296-1305. 3. Kumada T, Toyoda H, Kiriyama S, et al. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol. 2011;46(4):536-44.
OBSERVATION.galad_model_for_hepatocellular_carcinoma_hcc.v0
